vs
博士伦健康（BHC）与Burlington Stores, Inc.（BURL）财务数据对比。点击上方公司名可切换其他公司
博士伦健康的季度营收约是Burlington Stores, Inc.的1.0倍（$2.8B vs $2.7B），Burlington Stores, Inc.净利率更高（3.9% vs -3.7%，领先7.6%），博士伦健康同比增速更快（9.3% vs 7.1%），博士伦健康自由现金流更多（$403.0M vs $-109.6M），过去两年博士伦健康的营收复合增速更高（14.0% vs -6.9%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
伯灵顿百货（前身为伯灵顿大衣厂）是美国知名全国性折扣零售商，在全美46个州及波多黎各拥有超过1138家门店，总部位于新泽西州伯灵顿镇。2007年公司被贝恩资本收购，2008年汤姆·金斯伯里出任总裁兼首席执行官，2013年重新上市，现为美国第三大折扣零售企业。
BHC vs BURL — 直观对比
营收规模更大
BHC
是对方的1.0倍
$2.7B
营收增速更快
BHC
高出2.1%
7.1%
净利率更高
BURL
高出7.6%
-3.7%
自由现金流更多
BHC
多$512.6M
$-109.6M
两年增速更快
BHC
近两年复合增速
-6.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $2.7B |
| 净利润 | $-103.0M | $104.8M |
| 毛利率 | — | 44.2% |
| 营业利润率 | 17.0% | 5.1% |
| 净利率 | -3.7% | 3.9% |
| 营收同比 | 9.3% | 7.1% |
| 净利润同比 | -205.1% | 15.6% |
| 每股收益（稀释后） | $-0.30 | $1.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCBURL
| Q4 25 | $2.8B | $2.7B | ||
| Q3 25 | $2.7B | $2.7B | ||
| Q2 25 | $2.5B | $2.5B | ||
| Q1 25 | $2.3B | $3.3B | ||
| Q4 24 | $2.6B | $2.5B | ||
| Q3 24 | $2.5B | $2.5B | ||
| Q2 24 | $2.4B | $2.4B | ||
| Q1 24 | $2.2B | $3.1B |
净利润BHCBURL
| Q4 25 | $-103.0M | $104.8M | ||
| Q3 25 | $179.0M | $94.2M | ||
| Q2 25 | $148.0M | $100.8M | ||
| Q1 25 | $-58.0M | $260.8M | ||
| Q4 24 | $98.0M | $90.6M | ||
| Q3 24 | $-85.0M | $73.8M | ||
| Q2 24 | $10.0M | $78.5M | ||
| Q1 24 | $-64.0M | $227.5M |
毛利率BHCBURL
| Q4 25 | — | 44.2% | ||
| Q3 25 | — | 43.7% | ||
| Q2 25 | — | 43.8% | ||
| Q1 25 | — | 42.9% | ||
| Q4 24 | — | 43.9% | ||
| Q3 24 | — | 42.8% | ||
| Q2 24 | — | 43.5% | ||
| Q1 24 | — | 42.7% |
营业利润率BHCBURL
| Q4 25 | 17.0% | 5.1% | ||
| Q3 25 | 23.1% | 4.7% | ||
| Q2 25 | 17.5% | 5.3% | ||
| Q1 25 | 12.2% | 10.6% | ||
| Q4 24 | 21.8% | 4.7% | ||
| Q3 24 | 12.7% | 4.0% | ||
| Q2 24 | 16.2% | 4.7% | ||
| Q1 24 | 13.1% | 10.0% |
净利率BHCBURL
| Q4 25 | -3.7% | 3.9% | ||
| Q3 25 | 6.7% | 3.5% | ||
| Q2 25 | 5.8% | 4.0% | ||
| Q1 25 | -2.6% | 8.0% | ||
| Q4 24 | 3.8% | 3.6% | ||
| Q3 24 | -3.4% | 3.0% | ||
| Q2 24 | 0.4% | 3.3% | ||
| Q1 24 | -3.0% | 7.3% |
每股收益（稀释后）BHCBURL
| Q4 25 | $-0.30 | $1.63 | ||
| Q3 25 | $0.48 | $1.47 | ||
| Q2 25 | $0.40 | $1.58 | ||
| Q1 25 | $-0.16 | $4.03 | ||
| Q4 24 | $0.24 | $1.40 | ||
| Q3 24 | $-0.23 | $1.15 | ||
| Q2 24 | $0.03 | $1.22 | ||
| Q1 24 | $-0.17 | $3.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $584.1M |
| 总债务越低越好 | $20.8B | $2.0B |
| 股东权益账面价值 | $-554.0M | $1.5B |
| 总资产 | $26.4B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 1.32× |
8季度趋势，按日历期对齐
现金及短期投资BHCBURL
| Q4 25 | $1.3B | $584.1M | ||
| Q3 25 | $1.3B | $747.6M | ||
| Q2 25 | $1.7B | $371.1M | ||
| Q1 25 | $1.1B | $994.7M | ||
| Q4 24 | $1.2B | $857.8M | ||
| Q3 24 | $719.0M | $659.9M | ||
| Q2 24 | $595.0M | $742.3M | ||
| Q1 24 | $733.0M | $925.4M |
总债务BHCBURL
| Q4 25 | $20.8B | $2.0B | ||
| Q3 25 | $21.0B | $2.0B | ||
| Q2 25 | $21.7B | $1.6B | ||
| Q1 25 | $21.5B | $1.5B | ||
| Q4 24 | $21.6B | $1.5B | ||
| Q3 24 | $21.5B | $1.2B | ||
| Q2 24 | $21.7B | $1.2B | ||
| Q1 24 | $22.1B | $1.4B |
股东权益BHCBURL
| Q4 25 | $-554.0M | $1.5B | ||
| Q3 25 | $-565.0M | $1.4B | ||
| Q2 25 | $-764.0M | $1.4B | ||
| Q1 25 | $-1.2B | $1.4B | ||
| Q4 24 | $-1.3B | $1.1B | ||
| Q3 24 | $-1.2B | $1.1B | ||
| Q2 24 | $-1.2B | $1.0B | ||
| Q1 24 | $-1.1B | $996.9M |
总资产BHCBURL
| Q4 25 | $26.4B | $9.6B | ||
| Q3 25 | $26.8B | $9.3B | ||
| Q2 25 | $27.3B | $8.5B | ||
| Q1 25 | $26.4B | $8.8B | ||
| Q4 24 | $26.5B | $8.4B | ||
| Q3 24 | $26.5B | $7.8B | ||
| Q2 24 | $26.5B | $7.7B | ||
| Q1 24 | $26.9B | $7.7B |
负债/权益比BHCBURL
| Q4 25 | — | 1.32× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.21× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 1.35× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 1.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | $143.3M |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $-109.6M |
| 自由现金流率自由现金流/营收 | 14.4% | -4.1% |
| 资本支出强度资本支出/营收 | 3.3% | 9.3% |
| 现金转化率经营现金流/净利润 | — | 1.37× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $-358.5M |
8季度趋势，按日历期对齐
经营现金流BHCBURL
| Q4 25 | $495.0M | $143.3M | ||
| Q3 25 | $405.0M | $179.4M | ||
| Q2 25 | $289.0M | $-28.9M | ||
| Q1 25 | $211.0M | $543.2M | ||
| Q4 24 | $601.0M | $110.4M | ||
| Q3 24 | $405.0M | $160.4M | ||
| Q2 24 | $380.0M | $49.4M | ||
| Q1 24 | $211.0M | $598.5M |
自由现金流BHCBURL
| Q4 25 | $403.0M | $-109.6M | ||
| Q3 25 | $314.0M | $-101.0K | ||
| Q2 25 | $190.0M | $-438.6M | ||
| Q1 25 | $96.0M | $189.8M | ||
| Q4 24 | $495.0M | $-56.2M | ||
| Q3 24 | $334.0M | $-35.2M | ||
| Q2 24 | $302.0M | $-115.5M | ||
| Q1 24 | $129.0M | $410.3M |
自由现金流率BHCBURL
| Q4 25 | 14.4% | -4.1% | ||
| Q3 25 | 11.7% | -0.0% | ||
| Q2 25 | 7.5% | -17.5% | ||
| Q1 25 | 4.2% | 5.8% | ||
| Q4 24 | 19.3% | -2.2% | ||
| Q3 24 | 13.3% | -1.4% | ||
| Q2 24 | 12.6% | -4.9% | ||
| Q1 24 | 6.0% | 13.1% |
资本支出强度BHCBURL
| Q4 25 | 3.3% | 9.3% | ||
| Q3 25 | 3.4% | 6.6% | ||
| Q2 25 | 3.9% | 16.4% | ||
| Q1 25 | 5.1% | 10.8% | ||
| Q4 24 | 4.1% | 6.6% | ||
| Q3 24 | 2.8% | 7.9% | ||
| Q2 24 | 3.2% | 7.0% | ||
| Q1 24 | 3.8% | 6.0% |
现金转化率BHCBURL
| Q4 25 | — | 1.37× | ||
| Q3 25 | 2.26× | 1.91× | ||
| Q2 25 | 1.95× | -0.29× | ||
| Q1 25 | — | 2.08× | ||
| Q4 24 | 6.13× | 1.22× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | 38.00× | 0.63× | ||
| Q1 24 | — | 2.63× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
BURL
暂无分部数据
